within Pharmacolibrary.Drugs.ATC.L;

model L01EB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 14.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,
    adminCount     = 1,
    Vd             = 0.918,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009,
    Tlag           = 1020
  );

  annotation(Documentation(
    info ="<html><body><p>Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M mutation-positive NSCLC. It is currently approved and widely used for this purpose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of osimertinib in adult patients with advanced EGFR T790M mutation-positive NSCLC after oral administration.</p><h4>References</h4><ol><li><p>Tsutani, Y, et al., &amp; He, J (2023). Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. <i>Clinical lung cancer</i> 24(4) 376–380. DOI:<a href=&quot;https://doi.org/10.1016/j.cllc.2023.02.002&quot;>10.1016/j.cllc.2023.02.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36872181/&quot;>https://pubmed.ncbi.nlm.nih.gov/36872181</a></p></li><li><p>Ballard, P, et al., &amp; Cross, D (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 22(20) 5130–5140. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-16-0399&quot;>10.1158/1078-0432.CCR-16-0399</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27435396/&quot;>https://pubmed.ncbi.nlm.nih.gov/27435396</a></p></li><li><p>Vishwanathan, K, et al., &amp; Harvey, RD (2018). The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British journal of clinical pharmacology</i> 84(6) 1156–1169. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13534&quot;>10.1111/bcp.13534</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29381826/&quot;>https://pubmed.ncbi.nlm.nih.gov/29381826</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EB04;
